霍格瓦克斯:利用表位重叠来最大限度地覆盖疫苗设计中的人口,并应用于SARS-CoV-2
Sara C Schulte1, Alexander T Dilthey2, Gunnar W Klau1
1Algorithmic Bioinformatics, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Cell systems
|December 21, 2023
概括
霍格瓦克斯通过识别重叠来优化表位疫苗设计,以最大限度地覆盖人口. 这种方法可以确保高比例的个体得到SARS-CoV-2疫苗的有效免疫.
科学领域:
- 疫苗学 疫苗学 疫苗学
- 免疫信息学是指免疫信息学.
- 计算生物学 计算生物学
背景情况:
- 型疫苗的有效性取决于所选型及其由主要基因相容性复合体 (MHC) 蛋白呈现.
- 高MHC多态性和可变的结亲和性对疫苗设计中广泛覆盖人口构成挑战.
- 疫苗构造的物理限制进一步复杂化了基于表位素的有效疫苗的开发.
研究的目的:
- 介绍HOGVAX,一种用于设计表位疫苗的新型组合优化方法.
- 通过有效利用有限的疫苗建设空间来提高人口覆盖率.
- 在疫苗开发中应对MHC多态和MHC-结合所带来的挑战.
主要方法:
- 霍格瓦克斯使用层次重叠图 (HOG) 来识别和利用所选之间的重叠.
- 该方法明确地模拟了MHC内的链接不平衡结构.
- 一个涉及SARS-CoV-2表位体的案例研究被用于评估HOGVAX方法.
主要成果:
- 与使用连接的疫苗相比,HOGVAX设计的疫苗包含了显著更多的表位.
- 该方法预测了超过98%的人口的疫苗疗效.
- 用HOGVAX设计的疫苗确保在接种疫苗的个体中呈现的的数量很高.
结论:
- 霍格瓦克斯为设计具有改善人口覆盖率的表位疫苗提供了一种有效的策略.
- 组合优化方法成功克服了与MHC多态性相关的局限性.
- 这种方法有望开发针对SARS-CoV-2等病原体的广泛保护性疫苗.
更多相关视频
08:07Author Spotlight: Advancing Antiviral Strategies Through Novel Immunocapture and Mass Spectrometry Techniques
Published on: January 12, 2024
749
05:15Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
Published on: February 10, 2022
3.6K
相关概念视频
Conjugated Proteins
18.3K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.3K
Cross-reactivity
31.1K
Overview
31.1K
